Looking for the best hair fall treatment backed by science? Medical treatments for hair loss — including prescription medicine for hair loss like Minoxidil, Finasteride and Dutasteride — are the first-line approach recommended by IADVL and international dermatology guidelines for androgenetic alopecia and telogen effluvium. These proven hair fall solutions address the root cause before any surgical or regenerative intervention. Minoxidil (topical and oral) and Finasteride (1 mg daily for men) are both US-FDA approved specifically for hair regrowth. Oral Minoxidil at low doses (0.25–2.5 mg daily) is emerging as a highly effective, well-tolerated option. Dutasteride offers superior DHT suppression compared to Finasteride in resistant cases. For women, Spironolactone and topical Minoxidil are the best hair loss treatment for female pattern hair loss. Low-Level Laser Therapy (LLLT) is the only US-FDA cleared device therapy for hair loss and works synergistically with medications. At DermaVue, our hair loss doctors — board-certified dermatologists — evaluate each patient's hair loss pattern, severity, hormonal profile, and medical history before prescribing personalised, evidence-based medication protocols. Available at all 7 DermaVue clinics across Kerala and Coimbatore.
Hair loss treatment begins with an accurate diagnosis. The underlying cause determines the medication protocol — a prescription appropriate for androgenetic alopecia (AGA) may be ineffective or harmful in alopecia areata or telogen effluvium.
Pattern hair loss affects approximately 50% of men by age 50 and 40% of women by age 70 in India. The mechanism is DHT (dihydrotestosterone) sensitivity at the hair follicle — miniaturising follicles progressively produce thinner, shorter hairs until they stop entirely.
First-line treatments target this DHT pathway or directly stimulate follicular activity:
| Medication | Mechanism | Evidence Grade | Who For |
|---|---|---|---|
| Topical Minoxidil 5% | Vasodilation + follicle stimulation | Grade A (FDA approved) | Men & Women |
| Oral Minoxidil (low dose) | Systemic follicle stimulation | Grade A (emerging) | Both |
| Finasteride 1 mg | 5α-reductase type II inhibitor | Grade A (FDA approved) | Men only |
| Dutasteride 0.5 mg | 5α-reductase type I + II inhibitor | Grade A (India + S. Korea) | Men (off-label women) |
| Spironolactone 50–200 mg | Anti-androgen | Grade B | Women only |
| LLLT (laser cap/comb) | Photobiomodulation | Grade A (FDA cleared) | Men & Women |
Telogen effluvium (TE) is diffuse hair shedding triggered by physiological stress: post-COVID hair loss, postpartum hair loss, nutritional deficiencies (iron, Vitamin D, zinc), thyroid dysfunction, or crash dieting. Treatment addresses the root cause plus supportive therapy (oral supplements, topical Minoxidil if prolonged).
At DermaVue, blood panels are standard before prescribing — ruling out thyroid disorders, iron deficiency anaemia, and vitamin deficiencies before attributing hair loss to androgenetic causes.
Minoxidil is the most widely used hair loss medication globally. Originally a blood pressure drug, its hair growth effect was discovered as a side effect. Both topical and oral forms are effective — with meaningfully different profiles.
Available as 2% (women) and 5% (men and women) solutions and foam. Applied once or twice daily to the scalp. Prolongs anagen (growth) phase and improves follicular blood supply.
Doses 0.25–2.5 mg daily — far below the antihypertensive dose of 10–40 mg. Rapidly gaining evidence since 2021.
DHT blockers are the most important category for male androgenetic alopecia. They halt progression by blocking the enzyme (5α-reductase) that converts testosterone to DHT.
Women's hair loss is frequently under-diagnosed and under-treated. The treatment approach differs significantly from men due to hormonal considerations and medication safety profiles.
Diffuse thinning primarily at the crown and mid-scalp with preservation of the frontal hairline. Affects 12% of women by age 29, rising to 40% by age 70.
Affects 40–50% of women within 3–6 months of delivery. Reassurance and nutritional supplementation (iron, biotin, Vitamin D) are primary management. Topical Minoxidil can be used but is generally avoided during breastfeeding.
Iron deficiency is the single most reversible cause of hair loss in Indian women. Ferritin below 40 ng/mL correlates with poor hair growth even without frank anaemia. At DermaVue, a full panel including Ferritin, Vitamin D, TSH, and zinc is standard before attributing hair loss to pattern baldness.
LLLT is the only US-FDA cleared device therapy for both male and female pattern hair loss. It uses photons of red or near-infrared light (typically 630–670 nm wavelength) to stimulate follicular activity through photobiomodulation.
Photons are absorbed by cytochrome c oxidase in follicular mitochondria, increasing ATP production, reducing oxidative stress, improving blood flow, and extending the anagen growth phase. Multiple meta-analyses (including Lee et al., 2021) confirm significant improvement in hair density and thickness vs sham treatment.
This is the single most common patient frustration — medications take months before results become visible, and early hair shedding can paradoxically occur in the first 6–8 weeks (a positive sign of follicular cycle reset).
No visible change; possible increased shedding (normal)
Reduced hair fall in some patients
Early fine regrowth visible in good responders
Measurable improvement in hair density on trichoscopy
Maximum benefit assessment — key evaluation point
Stable maintenance if treatment continued
| Treatment | Cost (Approx.) | Frequency |
|---|---|---|
| Dermatologist consultation | ₹300–₹500 | Initial + follow-up |
| Topical Minoxidil 5% | ₹400–₹800/month | Daily |
| Finasteride 1 mg | ₹500–₹1,200/month | Daily |
| Dutasteride 0.5 mg | ₹800–₹1,500/month | Daily |
| Oral Minoxidil (low dose) | ₹300–₹700/month | Daily |
| LLLT session (clinic) | ₹1,500–₹3,000/session | Weekly/biweekly |
| Nutritional supplements | ₹500–₹1,500/month | Daily |
| Blood panel (baseline) | ₹1,500–₹3,000 | Once/6 months |
Medical management is significantly more cost-effective than regenerative therapies over the long term. It is also the only approach that halts disease progression — regenerative treatments like PRP stimulate growth but do not stop ongoing miniaturisation.
Board-certified dermatologist consultation from ₹300. Personalised medication protocol based on trichoscopy, blood panels, and IADVL guidelines.